{"organizations": [], "uuid": "c48c512df0da587f7ef34de64e2bfa0dd7829c91", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "https://fm.cnbc.com/applications/cnbc.com/resources/img/editorial/2018/02/15/105011317-RTS1H3Y3.1910x1000.jpg", "site_section": "", "section_title": "", "url": "https://www.cnbc.com/2018/02/15/jp-morgan-upgrades-two-biotech-companies-amid-optimistic-outlook.html", "country": "US", "domain_rank": 767, "title": "JP Morgan upgrades two biotech companies amid 'optimistic' outlook", "performance_score": 0, "site": "cnbc.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-15T23:01:00.000+02:00", "replies_count": 0, "uuid": "c48c512df0da587f7ef34de64e2bfa0dd7829c91"}, "author": "Thomas Franck", "url": "https://www.cnbc.com/2018/02/15/jp-morgan-upgrades-two-biotech-companies-amid-optimistic-outlook.html", "ord_in_thread": 0, "title": "JP Morgan upgrades two biotech companies amid 'optimistic' outlook", "locations": [], "entities": {"persons": [{"name": "adam jourdan", "sentiment": "negative"}, {"name": "cory kasimov", "sentiment": "none"}, {"name": "j.p. morgan", "sentiment": "none"}], "locations": [{"name": "zai lab", "sentiment": "none"}, {"name": "shanghai", "sentiment": "none"}, {"name": "china", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "jp morgan", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "j.p. morgan", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Adam Jourdan | Reuters A scientist works at Zai Lab's drug development facility in Shanghai, China. \nJ.P. Morgan alerted clients to two biotech companies that it believes could outperform peers in the next year. \nThough bullish biotech as a whole, analysts at the firm announced that they were upgrading a pair of stocks to overweight. \n\"Overall, we remain optimistic about the outlook for biotech in 2018, despite recent volatility giving back some early outperformance to start the year,\" wrote analyst Cory Kasimov on Wednesday. \"Indeed, the combination of continued innovation, a constructive FDA, and ready access to capital markets, all under the auspices of an omnipresent M&A backdrop, presents a compelling setup.\" \nHere are the two stocks J.P. Morgan upgraded to overweight during the firm's ongoing rating rebalancing. ", "external_links": [], "published": "2018-02-15T23:01:00.000+02:00", "crawled": "2018-02-15T23:17:24.006+02:00", "highlightTitle": ""}